OR WAIT null SECS
Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 5, 2021.
Tocilizumab is an interleukin 6 (an inflammatory cytokine) inhibitor approved for treating a variety of rheumatic diseases, including rheumatoid arthritis. As studies have shown that an increased level of interleukin 6 directly correlates to poor COVID-19 outcomes, investigators speculated that blocking this activity could be a helpful tool in treating the virus and lessening its severity.
The primary objective of this retrospective study was to understand why Latino patients were being disproportionately affected by COVID-19. Of the patients observed, 32 (18%) developed COVID-19 during the study period, meaning incidence rates were 5- to 11-fold higher than the general population (1,540 to 3,431/100,000).
This week, we sat down for an interview with Alice Fike, MS, NP, from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), to discuss her study titled “Risk factors for COVID-19 and rheumatic disease flare in a US cohort of Latino patients.” The primary objective of this retrospective study was to understand why Latino patients were being disproportionately affected by coronavirus disease 2019 (COVID-19).
In this 48-week, phase 3, randomized controlled trial, investigators examined patient-reported outcomes of patients with psoriatic arthritis receiving methotrexate monotherapy, etanercept monotherapy, or a combination of both drugs.
This week's rheumatoid arthritis quiz was developed by Fotios Koumpouras, MD, Director of Education and Training and Director of the Yale Lupus Program at Yale School of Medicine.